Breaking News

Swiss National Bank Introduces Negative Interest Rate of -0.25%
Tweet TWEET

BSD Medical Signs Exclusive Agreement for Distribution of BSD’s Cancer Treatment Hyperthermia System in Taiwan

  BSD Medical Signs Exclusive Agreement for Distribution of BSD’s Cancer
  Treatment Hyperthermia System in Taiwan

Business Wire

SALT LAKE CITY -- March 20, 2013

BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com), a
leading provider of medical systems that utilize heat therapy to treat cancer,
announced today that the Company has signed an exclusive agreement with Linden
Bioscence Co., Ltd. (Linden), a Taiwan corporation, for the sale and
distribution of BSD’s hyperthermia products in Taiwan.

Linden’s primary focus will be licensing, marketing and selling the BSD-2000
Hyperthermia System (BSD-2000) in Taiwan. Linden is funded by a large
Taiwanese philanthropic cancer foundation. Per the agreement, Linden is
required to purchase a minimum number of BSD-2000 systems annually over a five
year period, totaling a cumulative $7.1 million in revenue to BSD. Shipment of
the first hyperthermia systems will coincide with Linden’s receipt of Taiwan
FDA import license approval.

“We are pleased to have a focused, well-funded organization such as Linden as
our distribution partner in Taiwan,” stated Harold R. Wolcott, President of
BSD Medical. “The Asia Pacific countries are becoming an increasingly
important market and could represent up to 40% of the global health care
market by 2015. With the addition of Taiwan, our exclusive Asian distributors
have committed to minimum purchases, which could total more than $26.0 million
in revenue to BSD over a five year period.”

Taiwan ranks as one of the world’s leading economies, with a population of
23.3 million and overall GDP among the top 20 in the world. As a result, much
of the population expects a high level of medical care. The Taiwan medical
equipment market is focused on high-end, innovative technology, with a strong
reliance on imported products.

About the BSD Hyperthermia Systems

The BSD-2000 – developed and patented exclusively by BSD – delivers localized
therapeutic heating (hyperthermia) by applying radiofrequency (RF) energy. The
BSD-2000 creates a central focusing of energy that can be electronically
focused to target the shape, size and location of the tumor, thus providing
dynamic control of the heating delivered to the tumor region. The BSD-2000 has
Humanitarian Device Exemption (HDE) marketing approval from the U.S. Food and
Drug Administration (FDA) for use in conjunction with radiation therapy for
the treatment of cervical cancer patients who are ineligible for chemotherapy.
The BSD-2000 also has CE (Conformité Européenne) Marking approval for the
commercial sale in Europe. CE Marking approval is also recognized in many
countries outside of the EU.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems
to treat cancer and benign diseases using heat therapy, which is delivered
using focused radiofrequency (RF) and microwave energy. BSD’s product lines
include both hyperthermia and ablation treatment systems. BSD’s hyperthermia
cancer treatment systems, which have been in use for several years in the
United States, Europe and Asia, are used to treat certain tumors with heat
(hyperthermia), while increasing the effectiveness of other therapies such as
radiation therapy. BSD’s microwave ablation system has been developed as a
stand-alone therapy to employ precision-guided microwave energy to ablate
(destroy) soft tissue. The Company has developed extensive intellectual
property, multiple products in the market and established distribution in the
United States, Europe and Asia. Certain of the Company’s products have
received regulatory approvals and clearances in the United States, Europe and
China. For further information visit BSD Medical's website at
www.BSDMedical.com.

Statements contained in this press release that are not historical facts are
forward-looking statements, as defined in the Private Securities Litigation
Reform Act of 1995. All forward-looking statements are subject to risks and
uncertainties detailed in the Company's filings with the Securities and
Exchange Commission. These forward-looking statements speak only as of the
date on which such statements are made, and the Company undertakes no
obligation to update such statements to reflect events or circumstances
arising after such date.

Contact:

BSD Medical Corporation
William Barth, 801-972-5555
fax: 801-972-5930
investor@bsdmc.com
 
Press spacebar to pause and continue. Press esc to stop.